Related Experiment Video

Updated: Oct 31, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.2K

Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway

Daping Fan1, Shihuan Yu1, Yue Yang1

  • 1Department of Respiratory, First Affiliated Hospital of Harbin Medical University.

Biological & Pharmaceutical Bulletin
|July 1, 2021
PubMed

Insights

RASAL2 acts as a tumor suppressor in non-small cell lung cancer (NSCLC). Its downregulation promotes cancer cell invasion and metastasis via the Ras/ERK pathway, suggesting Rasal2 as a potential prognostic biomarker for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • RAS protein activator like 2 (Rasal2) exhibits varied roles in different cancers, acting as a tumor suppressor in some and oncogenic in others.
  • The specific function of Rasal2 in non-small cell lung cancer (NSCLC) remains largely uncharacterized.

Purpose of the Study:

  • To investigate the role of Rasal2 in the development and progression of NSCLC.
  • To elucidate the underlying molecular mechanisms by which Rasal2 influences NSCLC behavior.

Main Methods:

  • Quantitative PCR and immunoblotting to assess Rasal2 expression in NSCLC tissues and cell lines.
  • Functional assays including siRNA-mediated knockdown, transwell migration/invasion assays, and MTT assays.
  • Analysis of clinical data to correlate Rasal2 expression with patient outcomes and clinicopathological features.

Main Results:

  • Rasal2 expression was significantly downregulated in human NSCLC tissues and cell lines.
  • Low Rasal2 levels correlated with increased tumor thickness, ulceration, and advanced TNM staging.
  • Rasal2 knockdown enhanced NSCLC cell invasion and migration, linked to increased Ras/ERK pathway activation.

Conclusions:

  • Rasal2 functions as a suppressor of epithelial-mesenchymal transition (EMT) and metastasis in NSCLC.
  • The Ras/ERK signaling pathway is a key mechanism mediating Rasal2's tumor-suppressive effects.
  • Rasal2 holds potential as a prognostic biomarker for NSCLC.
Keywords:
RAS protein activator like 2 (Rasal2)Ras pathwayextracellular signal-regulated kinase (ERK) pathwaymetastasisnon-small cell lung cancer (NSCLC)

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K